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Abstract
Background: Genetic heterogeneity and compound heterozygosis give rise to a con-
tinuous spectrum of phenylalanine hydroxylase deficiency and metabolic phenotypes 
in phenylketonuria (PKU). The most used parameters for evaluating phenotype in 
PKU are pretreatment phenylalanine (Phe) levels, tolerance for dietary Phe, and Phe 
overloading test. Phenotype can vary from a “classic” (severe) form to mild hyperphe-
nylalaninemia, which does not require dietary treatment. A subset of patients is re-
sponsive to treatment by the cofactor tetrahydrobiopterin (BH4). Genotypes of PKU 
patients from Rio de Janeiro, Brazil, were compared to predicted and observed pheno-
types. Genotype‐based estimations of responsiveness to BH4 were also conducted.
Methods: Phenotype was defined by pretreatment Phe levels. A standard prediction 
system based on arbitrary assigned values was employed to measure genotype‐phe-
notype concordance. Patients were also estimated as BH4‐responders according to 
the responsiveness previously reported for their mutations and genotypes.
Results: A 48.3% concordance rate between genotype‐predicted and observed phe-
notypes was found. When the predicted phenotypes included those reported at the 
BIOPKU database, the concordance rate reached 77%. A total of 18 genotypes from 
30 patients (29.4%) were estimated as of potential or probable BH4 responsiveness. 
Inconsistencies were observed in genotypic combinations including the common 
“moderate” mutations p.R261Q, p.V388M, and p.I65T and the mild mutations 
p.L48S, p.R68S, and p.L249F.
Conclusion: The high discordance rate between genotype‐predicted and observed 
metabolic phenotypes in this study seems to be due partially to the high frequency of 
the so‐called “moderate” common mutations, p.R261Q, p.V388M, and p.I65T, 
which are reported to be associated to erratic or more severe than expected metabolic 
phenotypes. Although our results of BH4 estimated responsiveness must be regarded 
as tentative, it should be emphasized that genotyping and genotype‐phenotype 
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1 |  INTRODUCTION
Phenylketonuria (PKU; OMIM #261600) is a hereditary 
autosomal recessive disease characterized by an accumu-
lation of the amino acid phenylalanine (Phe) in blood and 
other tissues (Donlon, Sarkissian, Levy, & Scriver, 2014). 
The disease arises from a total or partial deficiency of the 
activity of the hepatic enzyme phenylalanine hydroxylase 
(PAH; EC 1.14.16.1), which catalyzes the conversion of 
Phe to tyrosine (Tyr) in the presence of the cofactor tet-
rahydrobiopterin (BH4) and nonheme iron (Sumaily & 
Mujamammi, 2017). This deficiency is caused by muta-
tions in the PAH gene—OMIM #612349 (Blau, Shen, & 
Carducci, 2014). PKU incidence varies widely among 
ethnic groups and countries (Blau et al., 2014). In Latin 
America (Borrajo, 2007) and Brazil (de Carvalho, dos 
Santos, dos Santos, Vargas, & Pedrosa, 2007), incidences 
of 1:21,000 (1:12,000–1:52,000) and 1:25,300 live births 
were estimated, respectively.
The degree of deficiency of PAH activity is very vari-
able among the affected individuals, which produces a 
continuous spectrum of metabolic phenotypes. The most 
used parameters of the metabolic phenotypes are pre-
treatment Phe levels, tolerance for dietary Phe, and Phe 
overloading test (Blau et al., 2014). Patients with suppos-
edly absent or near‐absent residual enzyme activity pres-
ent “classic” (severe) PKU, which is characterized by a 
pretreatment blood Phe level ≥1,200 μmol/L (≥20 mg/
dl) and a tolerance for dietary Phe of <20 mg/kg of body 
weight/day—250–350 mg/day (Guldberg et al., 1998; 
Michals‐Matalon, Bhatia, Guttler, Tyring, & Matalon, 
2007; Mitchell et al., 2005). The milder forms of PKU can 
be arbitrarily subdivided into moderate PKU (pretreatment 
Phe 900–1,200 μmol/L, 15–20 mg/dl) and mild PKU (pre-
treatment Phe 600–900 μmol/L, 10–15 mg/dl). Patients 
with moderate PKU present a tolerance for dietary Phe 
of 20–25 mg/kg of body weight/day (350–400 mg/day) 
and those with mild PKU tolerate 25–50 mg/kg of body 
weight/day (400–600 mg/day). Individuals who maintain 
levels of Phe in the range of 300–600 μmol/L (5–10 mg/
dl) on a normal diet are classified as having mild hyper-
phenylalaninemia (MHP). These individuals generally do 
not need diet therapy.
Genotypically, PKU is also very diverse. More than 
1,000 PAH gene variants are tabulated in the PAHvdb—
Phe Hydroxylase Gene Locus‐Specific Database (http://
www.biopku.org/pah/search-results-browse.asp), of which 
circa 630 are disease‐causing mutations (BIOPKU; http://
www.biopku.org/biopku/search-start.asp). In the PKU 
population of Rio de Janeiro, our group formerly found 37 
causative mutations, among a majority (91.2%) of com-
pound heterozygotes (Vieira Neto et al., 2018). Missense 
variants, variants at splicing sites, in‐frame deletions, de-
letions with frameshift, nonsense variants, and large de-
letions corresponded to 63.7%, 22.6%, 5.4%, 3.9%, 2.9%, 
and 1.5% of the mutant alleles, respectively (Vieira Neto 
et al., 2018).
Genotype‐phenotype correlation studies in PKU/MHP tra-
ditionally employ predicted PAH residual activity (PRA) of 
each mutation provided by in vitro experiments or by the anal-
ysis of its effect on protein structure (Danecka et al., 2015; 
Gjetting, Petersen, Guldberg, & Guttler, 2001; Pey, Desviat, 
Gamez, Ugarte, & Perez, 2003; Pey, Stricher, Serrano, & 
Martinez, 2007; Trunzo et al., 2016). Another approach for 
investigating genotype‐phenotype correlations is the analysis 
both of homoallelic mutant genotypes and of the so‐called 
“functionally hemizygous” heteroallelic genotypes, that is, 
patients who carry a functionally null mutation on one of 
their alleles and a missense or an in‐frame small deletion on 
the other (Kayaalp et al., 1997). Guldberg et al. (1998) pro-
posed a scale to evaluate genotype‐phenotype correlations 
by the severity of mutant alleles assigning them an arbitrary 
assigned value (AV) following this scheme: AV = 1, classic 
PKU; AV = 2, moderate PKU; AV = 4, mild PKU; AV = 8, 
MHP. The resultant sum of the two scores was correlated by 
the authors to the patient's phenotype.
Some mutations, usually found in mild to moderate PKU 
patients and presenting a significant PRA, are associated with 
BH4‐responsive PKU (Blau, 2016; Blau et al., 2014; Zurfluh 
et al., 2008).
In this study, the genotypes of PKU patients from Rio de 
Janeiro (Vieira Neto et al., 2018) were correlated to phenotypic 
severity, to Guldberg et al. (1998) scoring system and to pretreat-
ment Phe levels. Genotype‐based estimations of responsiveness 
to BH4, and the phenotypes of homoallelic and functionally 
hemizygous heteroallelic genotypes were also analyzed.
association studies are important in selecting patients to be offered a BH4 overload 
test, especially in low‐resource settings like Brazil.
K E Y W O R D S
Brazil, genetic association studies, genotype, hyperphenylalaninemia, phenotype, phenylalanine 
hydroxylase, phenylketonuria
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2 |  MATERIALS AND METHODS
2.1 | Subjects
Patients from a PKU metabolic center in Rio de Janeiro, 
Southeast Brazil, were invited to participate in this study. 
Of the approximately 150 patients with PKU followed in 
the reference center's outpatient clinics, a total of 102 pa-
tients from 95 families accepted to participate in this study. 
Ethical approval was obtained from the National Research 
Ethics Commission of Brazil. The study was performed in 
accordance with the Guidelines and Standards for Research 
in Human Beings, established by the Brazilian National 
Health Council (Brazil's Ministry of Health. National 
Health Council, 2013). Written informed consent was ob-
tained from each adult patient and parent or guardian of 
each child, adolescent and intellectually disabled patient 
enrolled in this study. Seven were late‐treated PKU pa-
tients (diagnosis of PKU of any severity phenotype after 
120 days of age), and the rest (95) were early‐treated pa-
tients detected by newborn screening. A total of 98 patients 
were assigned to one of the following four phenotypes 
according to pretreatment Phe levels in a recall sample 
after a positive newborn screening sample: classic PKU, 
≥1,200 μmol/L (≥20 mg/dl); moderate PKU, ≥900 μmol/L 
and <1,200 μmol/L (≥15 and <20 mg/dl); mild PKU, 
≥600 μmol/L and <900 μmol/L (≥10 and <15 mg/dl); 
MHP, ≥360 and <600 μmol/L (≥6 and <10 mg/dl). Four 
patients were allocated to one of these phenotypes as in-
dicated by the evaluation of a physician and a nutritionist.
2.2 | Genotype analysis
All patients were completely genotyped formerly by our 
group (Vieira Neto et al., 2018). Table 1 presents the mu-
tations found in these patients and their predicted PAH re-
sidual activities (null mutations pointed out) as indicated 
by Himmelreich et al. (2018), from previous publications 
(Aldamiz‐Echevarria et al., 2016; Eisensmith et al., 1996; 
Guldberg et al., 1998; Jeannesson‐Thivisol et al., 2015; 
Pey et al., 2003; Trunzo et al., 2016) or judged as null in 
the case of nonsense mutations, frameshift and large de-
letions whose PAH residual activities were not formerly 
reported.
2.3 | Genotype–phenotype 
correlations and genotype‐based estimations of 
BH4‐responsiveness
The predicted PRA was calculated for each genotypic com-
bination as an average from data compiled in Table 1. A 
phenotype prediction system based on arbitrary assigned 
values (AV) according to Guldberg et al. (1998) was 
employed to compare expected and observed phenotypes: 
AV = 1 was assigned to mutations that result in a nonfunc-
tional PAH enzyme phenotype (null mutations), including 
nonsense (introduction of a premature stop codon), most 
splice site mutations affecting the invariant AG‐GT dinu-
cleotides, small deletions with frameshift, some in‐frame 
deletions, large indels, and missense mutations that an in 
vitro expression analysis demonstrated an enzyme activ-
ity typically below <3% or <1% of normal (Kayaalp et al., 
1997)—these mutations when in homozygosis or in com-
pound heterozygosis with another null mutation produce 
typically a classic PKU phenotype; AV = 2, for moderate 
PKU mutations; AV = 4, for mild PKU mutations; and 
AV = 8 for MHP mutations. The resulting sums of the AVs 
of the genotypic combinations were interpreted according 
to Guldberg et al. (1998) method, which is summarized 
here: AV sum = 2, classic PKU; AV sum = 3, moderate 
PKU; AV sum = 4, moderate/mild PKU; AV sum = 5 or 
6, mild PKU; AV sum = 8, mild PKU/MHP; AV sum ≥ 9, 
MHP.
Estimated BH4 responsiveness of each mutation as a cate-
gorical variable (“Yes,” “No,” “Unclear” or “Unknown”) was 
based on the work of Zurfluh et al. (2008) and as indicated 
when analyzing the BIOPKU database (http://www.biopku.
org). A mutation was considered by Zurfluh et al. (2008) as 
associated with BH4‐responsiveness if it was present either 
in homozygosis or in compound heterozygosis with a known 
null mutation in patients that were classified as BH4‐respon-
sive—response to the oral administration of BH4 (10–20 mg/
kg body weight) by lowering their blood Phe levels by at least 
30% within 8–24 hr. In the BIOPKU database, the indication 
of BH4‐responsiveness of a mutation was taken into account 
when the majority of listed patients carrying it either in ho-
mozygosis or in compound heterozygosis with a known null 
mutation was classified as BH4‐responsive. Table 1 spec-
ifies the AV and BH4 responsiveness of each mutation by 
these two criteria in our patients. Patients were assigned as 
candidates for BH4 testing according to the criteria of Vela‐
Amieva et al. (2015): (a) genotypic combination previously 
reported as responsive by Aldamiz‐Echevarria et al. (2016), 
Jeannesson‐Thivisol et al. (2015), Scala et al. (2015), Couce 
et al. (2013), Karacic et al. (2009), or in the BIOPKU data-
base (http://www.biopku.org); (b) at least one mutant allele 
assigned as responsive by Zurfluh et al. (2008) or in the 
BIOPKU database; and (c) those patients whose genotypic 
combination has no documented evidence of responsiveness/
nonresponsiveness.
2.4 | “Functionally hemizygous” genetic 
combinations
The phenotypes of functionally hemizygous (Guldberg et al., 
1998) patients, that is, patients who carry a functionally null 
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mutation on one of their alleles, were used to evaluate the ef-
fect of missense alleles in some patients.
2.5 | Statistics
The statistical software package Stata/SE 12.1 for Mac 
(StataCorp) was employed to analyze the data. The relation-
ship between the predicted PAH residual activities and pre-
treatment Phe levels was evaluated by linear regression and 
Pearson's correlation coefficient. A two‐sample test of pro-
portions was used to compare genotype‐phenotype discord-
ance of genotypes containing p.R261Q, p.V388M, or p.I65T 
mutations with the discordance of other genotypes.
3 |  RESULTS
3.1 | Mutation and phenotype distributions
A total of 77 genotypic combinations were observed in our 
sample. Most of the genotypes (58/77, 75.3%) were found in 
just one patient (Table 2).
Of the 98 patients whose pretreatment Phe levels could 
be retrieved, 51 (52.0%) were classified as classic PKU, 25 
(25.5%) as moderate PKU, 19 (19.4%) as mild PKU, and 
three (3.1%) as MHP. Three classic and one mild PKU pa-
tients, with no pretreatment Phe levels data, were classified 
according to an evaluation by a physician and a nutritionist.
3.2 | The AV phenotype prediction system
In our sample, nine patients were homoallelic. Four of 
the five patients homoallelic for severe or null mutations 
(p.Q355_Y356insGLQ, formerly IVS10‐11G>A, p.Y166*, 
c.168+5G>C, and p.Y168Sfs*27) exhibited a classic pheno-
type in accordance to the AV system. However, one patient 
homoallelic for the p.R158Q mutation had a moderate pheno-
type. On the other hand, two of the four homoallelic patients 
for mutations with PRA ≥12%, p.V388M and p.R261Q, 
which by the AV system should present a moderate/mild 
phenotype, had a classic phenotype—discordance of 50% 
(Table 2).
Among the heteroallelic genotypes, 16 (20 patients) were 
combinations of null or severe mutations, 37 (52 patients) 
were “functionally hemizygous” genotypes and six geno-
types (eight patients) were combinations of two mutations 
with AV value ≥ 2 (Table 2).
In summary, the analysis of the 66 genotypes with infor-
mation on AV, comprising 89 patients, demonstrated that 
the observed phenotype matched the AV predicted pheno-
type in 48.3% of the cases (discordance rate of 51.7%). If 
the phenotypes reported for the genotypic combinations in 
BIOPKU database were included as consistent outcomes, the 
discordance rate fell to 23.1% (Table 2). Moreover, only five 
patients (5.6%) had an observed phenotype more than one 
category away from that predicted. Table 3 summarizes the 
results of the AV phenotypic prediction system.
Analyzing the genotype‐phenotype discordance in func-
tionally hemizygous patients, we found that patients carry-
ing the common moderate mutations p.R261Q, p.V388M, 
and p.I65T presented a high level of discordant phenotypes, 
usually more severe than expected. A total of 18 out of 34 
functionally hemizygous patients (53.0%) exhibited a clas-
sic, and 8 (23.5%) a mild phenotype. Only eight (23.5%) 
presented the expected moderate phenotype. Inconsistencies 
were also observed in genotypes involving a severe or null 
mutation and the mild mutations p.L48S, p.R68S, and 
p.L249F. None of the five patients presented the expected 
mild phenotype—four exhibited a classic and one a moder-
ate phenotype.
3.3 | Selected new genotypes
The genotypes involving the mutation c.1199+17G>A 
(rs62508613), p.[Q355_Y356insGLQ];c.[1199+17G>A], 
p.[D84Y];c.[1199+17G>A], c.[168+5G>C];[1199+17G>A], 
p.[R252W];c.[1199+17G>A], were found in two moderate/
mild PKU and two MHP patients. Three of these patients were 
functionally hemizygous patients.
T A B L E  3  Observed phenotypes based on pretreatment phenylalanine levels (85 patients) or clinical evaluation (four patients) versus 
expected phenotypes according to the sum of the arbitrary assigned values (AV) for each genotype, according to the phenotype prediction system 
of Guldberg et al. (1998) for patients with PKU or mild hyperphenylalaninemia (MHP) from Rio de Janeiro, Brazil
AV sum Expected phenotype
Observed phenotype
Total (expected)
Perfect 
matches, %Classic Moderate Mild MHP
2 Classic 21 4   25 84.0
3 Moderate 23 10 8  41 24.4
4 Moderate/mild 2 3 3  8 75.0
5 and 6 Mild 5 3 5  13 38.5
9 MHP   1 1 2 50.0
Total (observed)  51 20 17 1 89 48.3
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3.4 | Predicted PRA and pretreatment 
Phe levels
A strong relationship between mutation severity, according 
to the level of PRA, and the inverse of pretreatment Phe lev-
els was observed (t = 4.79, p < 0.0001)—Figure 1. Means 
(±SD) of PRA activity of classic, moderate, and mild PKU 
groups were 13.9% (12.4), 19.8% (11.1), and 29.1% (13.4), 
respectively. There was a statistically significant difference 
in PRA among these severity groups as determined by one‐
way ANOVA (F(2, 81) = 9.72, p = 0.0002). A Tukey test 
revealed that PRA was statistically significantly higher in 
the mild group compared to the classic group (p < 0.0001). 
However, there were no statistically significant differences 
between classic and moderate groups (p = 0.176), and be-
tween moderate and mild groups (p = 0.063).
3.5 | BH4 estimated responsiveness
Ten (27.0%) out of the 37 mutations found in our population 
were previously reported as BH4 responsive, 19 (51.4%) as 
nonresponsive. The BH4‐responsiveness of 7 (18.9%) muta-
tions has not been established up to this time, and one mu-
tation was first described by our group (Vieira Neto et al., 
2018)—Table 1.
Twelve patients (11.8%), corresponding to eight geno-
types, carried two responsive mutations. A total of 54 patients 
(52.9%), corresponding to 38 genotypes, carried one respon-
sive mutation. Thus, 66 patients (64.7%), distributed among 
46 genotypes, had at least one responsive mutation.
Fifteen genotypes, with at least one responsive allele, from 
26 patients (25.5%) were potentially responsive to BH4—un-
certain responsiveness to BH4 in Table 2. Three genotypes, 
with at least one responsive allele, from four patients (3.9%), 
had an extremely high probability of responsiveness to 
BH4—Y in Table 2. Ten genotypes from 13 patients (12.7%), 
with just one responsive allele, were estimated not to respond 
to BH4—N in Table 2. The BH4 responsiveness status of 18 
genotypes, from 23 patients (22.5%) carrying at least one 
responsive allele, could not be estimated—unknown respon-
siveness to BH4 in Table 2.
Eighteen genotypes, distributed among 22 patients 
(21.6%), were combinations of BH4 nonresponsive alleles. 
Ten of these genotypes, from 14 patients (13.7%), were es-
timated to be BH4 nonresponsive—Table 2. Eight genotypes 
from eight patients (7.8%), with two BH4 nonresponsive al-
leles, although probably also nonresponsive, as their BH4 re-
sponsiveness has not been reported yet, were considered as 
genotypes of unknown responsiveness to BH4—Table 2.
Eleven genotypes from 12 patients (11.8%) were combi-
nations of a nonresponsive allele with an allele of unknown 
responsiveness to BH4—they were considered as genotypes 
of unknown responsiveness to BH4—Table 2. Two genotypes 
from two patients (2.0%) were combinations of alleles of un-
known responsiveness to BH4.
In summary, 18 genotypes from 30 patients (29.4%) were 
estimated as genotypic combinations of potential or probable 
BH4 responsiveness; 28 genotypes from 35 patients (34.3%) 
were estimated as genotypes of improbable responsiveness 
to BH4; 31 genotypes from 37 patients (36.3%) were consid-
ered as genotypic combinations of unknown responsiveness 
to BH4.
Only 14 patients (13.7%), distributed among 10 genotypes 
composed of two nonresponsive alleles, were not considered 
as candidates for BH4 loading test. Nevertheless, eight (7.8%) 
patients from eight genotypes of unknown responsiveness to 
BH4, composed of two nonresponsive alleles, and 13 patients 
(12.7%), from ten genotypes estimated not to respond to 
BH4, with just one responsive allele, can also be considered 
as noncandidates for BH4 loading test. The usual 24 h BH4 
loading test may not be adequate for these 35 patients as they 
have a higher probability of being slow responders and need 
a longer period of time for this BH4 slow‐responsiveness to 
be observed.
4 |  DISCUSSION
A high degree of discordance (51.7%) was noticed in geno-
type‐phenotype correlations assessed by the arbitrary assigned 
F I G U R E  1  Comparison of the inverse of pretreatment 
phenylalanine (Phe) levels (mg/dl) with the predicted phenylalanine 
hydroxylase (PAH) enzyme activity for a total of 81 patients for 
which mutant PAH residual activity (PRA) for both alleles and 
pretreatment Phe levels were both known. Mean PRA for each 
genotype was established by data in BIOPKU database and previously 
published articles (Aldamiz‐Echevarria et al., 2016; Eisensmith 
et al., 1996; Guldberg et al., 1998; Jeannesson‐Thivisol et al., 2015; 
Pey et al., 2003; Trunzo et al., 2016). A significant correlation 
(t = 4.79, p < 0.0001) was found by linear regression analysis: 
y = 0.0007x + 0.0379, R2 = 0.225
0
.05
.1
.15
0 10 20 30 40 50
Predicted PAH activity (%)
1/Pre−treatment Phe Linear prediction
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values (AV) phenotype predictive system of Guldberg et al. 
(1998), modified by data from other researchers (Pey et al., 
2003; Trunzo et al., 2016), and, for some mutations, by our 
own assessment. Guldberg et al. (1998) found a much lower 
degree of discordance (circa 20%). There could be several 
reasons for this finding, but it seems that the high frequency 
of the so‐called “moderate” mutations, p.R261Q, p.V388M, 
and p.I65T is at the core of this high discordance.
Taking into account the 48 patients with genotypes 
containing p.R261Q, p.V388M, or p.I65T mutations and 
whose AV sum could be calculated, a higher discordance 
was reached—64.6%, significantly different from the dis-
cordance found in 41 patients with other genotypes—36.6% 
(z = 2.6349, p = 0.0084).
Functionally hemizygous genotypes and even homoal-
lelic genotypes containing the catalytic domain missense 
mutation p.R261Q, had an erratic correlation to phenotype. 
The seven heteroallelic genotypes containing a null mu-
tation and p.R261Q (functionally hemizygous genotypes) 
had different outcomes: six classic, three moderate, and 
three mild PKU individuals (Table 2). Even each of the 
three p.R261Q homozygous patients had a different phe-
notype: classic, moderate, and mild. This metabolic pheno-
typic variability is evident in the BIOPKU database where, 
of the 205 homozygous patients for the p.R261Q muta-
tion, 72 (35.1%) presented a mild PKU phenotype, while 
133 (64.9%) presented a classic PKU phenotype. Kayaalp 
et al. (1997) attributed this phenotypic variability to a 
possible negative complementation of this allele in vivo, 
which is not apparent in in vitro studies of residual activity. 
However, as this variability is found in both homoallelic 
and functionally hemizygous genotypes, it is improbable 
that it is a consequence of negative allelic complementa-
tion exclusively. Danecka et al. (2015) postulated that some 
genotypes that involved p.R261Q (p.[R261Q]; [R261Q], 
p.[R261Q];[R408W], p.[R261Q];[Q355_Y356insGLQ]) 
had better metabolic PAH function at higher Phe concen-
trations. Thus, individuals with these genotypes exhibit 
higher Phe tolerance when their plasma Phe levels are a 
little above the usual therapeutic threshold. However, it is 
less clear how this phenomenon could at least in part ex-
plain the significant phenotypic variability found in studies 
like ours that classified phenotypes on the basis of pretreat-
ment Phe levels and not Phe tolerance.
On the other hand, the genotypes containing the most fre-
quent mutation, p.V388M—also a catalytic domain missense 
mutation, presented a trend toward a more severe phenotype. 
One p.V388M homozygous patient exhibited a classic pheno-
type. The nine functionally hemizygous genotypes harboring 
p.V388M were distributed among seven classic, five moder-
ate, and four mild PKU patients (Table 2). This shift toward 
a phenotype more severe than expected by the AV system is 
documented in the BIOPKU database: of the 28 homozygous 
patients for the p.V388M mutation, 14 (50%) presented the 
mild and 14 (50%) the classic phenotype. We could find infor-
mation in the database for seven of the nine p.V388M func-
tionally hemizygous genotypes found in our study—three of 
them were reported exclusively in classic PKU patients, three 
in classic and mild, and only one was exclusively reported in 
mild phenotype patients. Other authors have also described 
this trend toward more severe phenotypes (Rivera et al., 2011; 
Santos et al., 2010). An explanation for this trend is still 
needed, as conflicting results regarding the variant protein 
V388M enzyme kinetics have been reported (Leandro, Rivera, 
Lechner, de Almeida, & Konecki, 2000; Staudigl et al., 2011).
Five of the six functionally hemizygous patients carrying 
p.I65T, a regulatory domain missense mutation, presented the 
classic, and just one the mild phenotype (Table 2). The dis-
tribution of functionally hemizygous individuals harboring 
p.I65T among different phenotype classes was already iden-
tified in the classical work of Guldberg et al. (1998). These 
authors speculated that a mechanism similar to the afore-
mentioned for p.R261Q was responsible for the phenotypic 
diversity of functionally hemizygous genotypes containing 
p.I65T, but this has not been confirmed by more recent stud-
ies (Danecka et al., 2015; Staudigl et al., 2011). Moreover, 
it is important to note that of the 34 homozygous patients 
for mutation p.I65T reported in the BIOPKU database, 25 
(73.5%) presented a mild phenotype but nine (26.5%) had a 
classic phenotype.
Sarkissian et al. (2012) analyzed the genotypes of patients 
that participated in the clinical trials of sapropterin, a syn-
thetic pharmacological form of BH4 (6R‐L‐erythro‐5,6,7,8 
tetrahydrobiopterin dihydrochloride). There are some in-
consistencies between these authors’ findings and those re-
ported at the BIOPKU database and by Zurfluh et al. (2008) 
based on BH4 loading tests (Tables 1 and 2). Sarkissian et al. 
(2012) reported p.V388M as an unresponsive mutation, 
whereas in the BIOPKU database, of the 14 homozygous 
patients for the p.V388M mutation tested for BH4 respon-
siveness, eight (57.14%) were responsive and two (14.29%) 
were slow responders. Zurfluh et al. (2008) also described 
it as a responsive mutation. Of the four genotypes involving 
p.V388M described by Sarkissian et al. (2012), three are re-
ported at the BIOPKU database: p.[V388M];[E390G]—all 
11 patients tested were BH4 responsive; c.[441+5G>T];p.
[V388M]—one (14.3%) responder, and two slow responders 
(28.6%) out of seven patients tested; p.[R158Q];[V388M]—
one slow responder (50%) out of two patients tested. Only the 
first genotype, p.[V388M];[E390G], was also reported as re-
sponsive in sapropterin clinical trials, according to Sarkissian 
et al. (2012). Among Ibero‐American patients tested by BH4 
loading tests, p.V388M appeared to be at least ambiguously 
responsive—of the three Spanish patients homozygous for 
this mutation reported by Aldamiz‐Echevarria et al. (2016), 
one was BH4 responsive, and in Brazil, Nalin et al. (2011) 
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reported one homozygous patient for p.V388M, and he was 
BH4 responsive.
Inconsistencies were also found in genotypes involving 
“mild” alleles. Four of the five heteroallelic functionally 
hemizygous genotypes involving the mutant alleles p.L48S, 
p.R68S, and p.L249F were observed in four classic PKU 
patients, and in just one patient with a moderate phenotype. 
Genotype‐phenotype inconsistencies have been formerly 
reported especially for genotypes harboring the mutation 
p.L48S (Danecka et al., 2015; Guldberg et al., 1998; Kayaalp 
et al., 1997; Pey et al., 2003). According to Danecka et al. 
(2015), the genotype p.[L48S];[Q355_Y356insGLQ], and 
other genotypes not found in our patients, present high PAH 
residual enzyme activity over a narrow range of Phe con-
centrations. Therefore, a behavior opposite to that found in 
p.R161Q genotypes is expected: individuals with these gen-
otypes might exhibit lower Phe tolerance when their plasma 
Phe levels are above the usual therapeutic threshold.
The mutation c.1199+17G>A (rs62508613) found in four 
genotypes, three of them with null mutations, was clearly 
linked to milder phenotypes—moderate/mild PKU or even 
MHP. There are few reports of this mutation in the litera-
ture. Acosta, Silva, Carvalho, and Zago (2001) were the first 
to describe it in a moderate PKU patient with the genotype 
p.[R261Q];c.[1199+17G>A]. There are only six individuals 
reported at ClinVar (Variation ID 102555), four of them the 
aforementioned patients from our study. Our findings give 
strong support to a high residual PAH activity for these gen-
otypes, thus conferring a mild phenotype. Nevertheless, the 
activity of c.1199+17G>A must be confirmed in vitro in eu-
karyotic cell systems.
Another factor that may be in part responsible for the high 
genotype‐phenotype discordance in our patients is the inclu-
sion of the moderate phenotype category. If the BIOPKU da-
tabase were used for phenotype prediction of 45 genotypes 
from 66 patients in our sample, the discordance would de-
crease to 19.7%; and if both prediction systems, the BIOPKU 
database and the AV system, were accepted as valid, the 
genotype‐phenotype discordance for 91 patients distributed 
among 67 genotypes would fall from 51.7% to 23.1%. The 
BIOPKU database uses the allelic phenotype value for pre-
dicting the metabolic phenotype of PAH variants and gen-
otypes (Garbade et al., 2018). Nevertheless, the “predicted” 
phenotypes from the BIOPKU database of Table 2 were the 
reported phenotypes of the patients tabulated in that data-
base. The BIOPKU database patient tabulation employs 
pretreatment blood Phe levels to categorize three phenotype 
categories—classic and mild PKU, and MHP, omitting the 
moderate PKU category. This simplification and the recog-
nition of an overlapping range in blood Phe levels between 
mild PKU and classic PKU may have produced a reduction 
in genotype‐phenotype discordance when BIOPKU database 
phenotype tabulation data were employed.
The method used in phenotype categorization in our study, 
pretreatment Phe levels, deserves some concern also. We 
found a moderate correlation between predicted PRA and the 
inverse of pretreatment Phe levels (r = 0.456, n = 80). Earlier 
work, summarized by Enns et al. (1999), also found this cor-
relation. But those authors themselves did not corroborate it. 
Rivera et al. (2000) obtained an even higher inverse correla-
tion among early‐treated patients with PKU from Portugal 
(r = −0.773, n = 37). Although this literature is rather old, its 
focal point—the use of pretreatment Phe levels for phenotype 
definition, is still pertinent nowadays. Pretreatment Phe lev-
els are still considered indispensable for phenotyping PKU as 
they permit classifying patients in the neonatal period (Blau, 
Hennermann, Langenbeck, & Lichter‐Konecki, 2011). They 
are extensively used for a three‐phenotype class tabulation of 
PKU patients in the BIOPKU database. Nevertheless, pre-
treatment Phe levels are especially dependent on the timing of 
newborn screening and on the diet the neonate was receiving 
at the time of blood sampling (Blau et al., 2011). Early hos-
pital discharge after birth, and specimen collection for new-
born screening <3 days of life, might have as a consequence 
the classification of PKU patients in milder categories. This 
was not an important issue in our study as the mean age at 
newborn screening specimen sampling for our early‐treated 
patients (95 out of a total of 102 patients) was 19 days.
Phe tolerance is a dependable alternative parameter for 
phenotyping PKU (Guldberg et al., 1998). It corresponds to 
the maximum amount of Phe an individual can consume and 
still maintain blood Phe levels within the therapeutic target 
range. Although Phe tolerance may be predictable already 
in 2‐year‐old infants, it is usually determined in children 
≥5 years of age. Moreover, Phe tolerance may be difficult 
to determine under nonstandardized conditions, as prescribed 
Phe intake often is much lower than the actual Phe intake 
(van Wegberg et al., 2017). Another caveat for using Phe 
tolerance for phenotype categorization is modulation by tar-
get plasma Phe levels that can lead to some inconsistencies 
(Danecka et al., 2015; Guldberg et al., 1998).
PAH genotyping and genotype‐phenotype associa-
tion studies may be employed as a screening tool for BH4 
responsiveness, considering the high cost of the drug sap-
ropterin—annual costs for a 29 kg patient were estimated 
at Can$24,000–Can$72,000 (CADTH Common Drug 
Reviews, 2017), especially in low‐resource settings, like 
Brazil (National Committee for Technology Incorporation—
CONITEC, 2018) and China (Zhu et al., 2017). Additionally, 
the accessibility to the drug is limited due to the decision of 
several health technology assessment agencies not to reim-
burse it, including the National Committee for Technology 
Incorporation (CONITEC) recommendation to fund it through 
the Brazilian Public Health System—SUS only for women 
in the preconception period and during pregnancy (National 
Committee for Technology Incorporation—CONITEC, 
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2018). The importance of the complete PAH genotype as a 
selection criterion for offering BH4 loading test and for es-
timating BH4 responsiveness has similarly been established 
in high income countries (Jeannesson‐Thivisol et al., 2015; 
Karacic et al., 2009).
A clinically meaningful definition of BH4 responsiveness 
is widely accepted as the observation of a 20%–30% reduc-
tion in blood Phe concentration (Blau, 2008; Levy, Burton, 
Cederbaum, & Scriver, 2007). Several protocols have been 
employed to demonstrate this reduction, as there is no con-
sensus regarding the best BH4 overload test (Giugliani et al., 
2011). The sequential first clinical trials of sapropterin—
Burton et al. (2007), Levy, Milanowski, et al. (2007) and Lee 
et al. (2008), defined responsiveness as a ≥30% reduction 
in Phe blood concentration relative to baseline values at the 
end of 8 days, but while the first two studies used a dose of 
sapropterin of 10 mg kg−1 day−1, Lee et al. (2008) evaluated 
daily doses of 5, 10, and 20 mg/kg to demonstrate a dose‐
response relationship in the reduction in basal Phe levels. 
All three studies considered the same population: patients 
nonadherent to the recommended dietary intake of Phe, age 
≥8 years old, presenting basal Phe levels ≥8 mg/dl. Trefz 
et al. (2009) confirmed that a dose of 20 mg kg−1 day−1 of 
sapropterin for 8 days was able to detect a higher response 
rate versus 5 mg kg−1 day−1 and 10 mg kg−1 day−1, but still 
maintained a ≥30% reduction in Phe blood concentration be-
tween Day 1 and Day 8 to define responsiveness.
As these multiple administrations of sapropterin and ex-
tension of the test to up to 8 days in the clinical trials are more 
expensive and definitely not practical for the initial screening 
(Blau, 2008), the BH4 loading test, known previously to these 
trials, standardized as a 24‐hr protocol after a single oral dose 
of 20 mg/kg of BH4 or sapropterin, was shown to be able to 
detect most responsive patients, using a cutoff of ≥30% re-
duction in Phe blood basal concentration (Blau & Erlandsen, 
2004; Fiege & Blau, 2007). The necessity to detect a small 
fraction of patients, so‐called “slow responders,” which 
needed a repeated administration of the drug, led some PKU 
centers in Europe to use a 48‐hr protocol with two consecutive 
BH4 administrations of 20 mg/kg (Fiege et al., 2005; Heintz, 
Cotton, & Blau, 2013; Scala et al., 2015). Meanwhile, in the 
USA, protocols involving multiple administrations of saprop-
terin up until 1 month of therapy are still preferred to define 
BH4‐responsiveness (Singh & Quirk, 2011; Utz et al., 2012).
PAH genotyping is a useful complementary tool to BH4 
loading test, as it can help reevaluate potential BH4 re-
sponsiveness misclassifications (Heintz et al., 2013; Quirk, 
Dobrowolski, Nelson, Coffee, & Singh, 2012). It is particu-
larly useful in the situation of apparently responsive patients 
in BH4 loading tests that eventually do not present significant 
increase in baseline dietary Phe tolerance and decrease in 
metabolic formula needs (Quirk et al., 2012).
There are also important features to be considered from 
genotypes when deciding which BH4 loading test to be used 
in our particular patient population. The usual 24 or 48‐hr 
BH4 loading test may not be adequate for patients that have 
two nonresponsive alleles or a nonresponsive genotype as 
they have a higher probability of being slow responders and 
need a longer period for this BH4 slow‐responsiveness to be 
observed (Zhu et al., 2017). A total of 35 (34.3%) patients in 
this study could be included in this category.
Excluding the patients having genotypic combinations of 
unknown responsiveness to BH4, 46.2% of our patients were 
estimated as potential or probable BH4‐responders. A small‐
scale study from Brazil, encompassing 18 patients, found six 
(33.3%) BH4‐responders (Nalin et al., 2011). As the preva-
lence of BH4 responsiveness has been variable in different 
studies (Somaraju & Merrin, 2015), we cannot make any 
assertion concerning the probability of the figures from our 
PAH genotyping study and Nalin et al. (2011) combined Phe 
and BH4 loading test study to be confirmed in future BH4 
loading tests of our PKU population.
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